Predicting In-Hospital Treatment Failure (≤7 days) in Patients with COPD Exacerbation Using Antibiotics and Systemic Steroids

COPD: Journal of Chronic Obstructive Pulmonary Disease

Volumn 13, Issue 1, 2016, Pages 82-92

  Crisafulli, Ernesto ^a   Torres, Antoni ^b   Huerta, Arturo ^b   Guerrero, Mónica ^b   Gabarrús, Albert ^b   Gimeno, Alexandra ^c   Martinez, Raquel ^c   Soler, Néstor ^b   Fernández, Laia ^b   Wedzicha, Jadwiga A ^d   Menéndez, Rosario ^c  

^a CARLO POMA HOSPITAL   (Italy)

^b HOSPITAL CLÍNIC   (Spain)

^c HOSPITAL UNIVERSITARIO LA FE   (Spain)

^d ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

Chronic obstructive pulmonary disease; disease exacerbation; infl ammatory response; predictors; treatment failure

Indexed keywords

C REACTIVE PROTEIN; CEPHALOSPORIN DERIVATIVE; INTERLEUKIN 10; INTERLEUKIN 8; MACROLIDE; PENICILLIN DERIVATIVE; PROCALCITONIN; QUINOLONE DERIVATIVE; STEROID; TUMOR NECROSIS FACTOR ALPHA; ANTIINFECTIVE AGENT; CALCA PROTEIN, HUMAN; CALCITONIN; CALCITONIN GENE RELATED PEPTIDE; GLUCOCORTICOID; IL10 PROTEIN, HUMAN; IL6 PROTEIN, HUMAN; IL8 PROTEIN, HUMAN; INTERLEUKIN 1; INTERLEUKIN 6; PROTEIN PRECURSOR; TUMOR NECROSIS FACTOR;

AGED; ANTIBIOTIC THERAPY; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COUGHING; DISEASE EXACERBATION; DISEASE SEVERITY; FEMALE; HOSPITAL PATIENT; HOSPITAL READMISSION; HOSPITALIZATION; HUMAN; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MICROBIOLOGICAL EXAMINATION; MORTALITY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; SYSTEMIC THERAPY; TREATMENT DURATION; TREATMENT FAILURE; COHORT ANALYSIS; DISEASE COURSE; FORCED EXPIRATORY VOLUME; LENGTH OF STAY; MENTAL HEALTH; METABOLISM; MIDDLE AGED; MULTIVARIATE ANALYSIS; PATHOPHYSIOLOGY; PNEUMONIA, BACTERIAL; PROGNOSIS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RISK FACTOR; STATISTICAL MODEL; STATISTICS AND NUMERICAL DATA; TIME FACTOR; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; C-REACTIVE PROTEIN; CALCITONIN; CALCITONIN GENE-RELATED PEPTIDE; COHORT STUDIES; DISEASE PROGRESSION; FEMALE; FORCED EXPIRATORY VOLUME; GLUCOCORTICOIDS; HOSPITALIZATION; HUMANS; INTERLEUKIN-1; INTERLEUKIN-10; INTERLEUKIN-6; INTERLEUKIN-8; LENGTH OF STAY; LOGISTIC MODELS; MALE; MENTAL STATUS SCHEDULE; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; PATIENT READMISSION; PNEUMONIA, BACTERIAL; PROGNOSIS; PROSPECTIVE STUDIES; PROTEIN PRECURSORS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RISK FACTORS; TIME FACTORS; TREATMENT FAILURE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84955367910     PISSN: 15412555     EISSN: 15412563     Source Type: Journal    
DOI: 10.3109/15412555.2015.1057276     Document Type: Article

References (36)

1. Buist AS, McBurnie MA, Vollmer WM, et al.; BOLD Collaborative Research Group. International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study. Lancet 2007; 370: 741-750.
2. Anthonisen NR, Manfreda J, Warren CP, et al. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 1987; 106: 196-204.
3. Papi A, Bellettato CM, Braccioni F, et al. Infections and airway inflammation in chronic obstructive pulmonary disease severe exacerbations. Am J Respir Crit Care Med 2006; 173: 1114-1121.
4. Connors AF Jr, Dawson NV, Thomas C, et al. Outcomes following acute exacerbation of severe chronic obstructive lung disease. The SUPPORT investigators (Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments). Am J Respir Crit Care Med 1996; 154: 959-967.
5. Wouters EF. The burden of COPD in The Netherlands: results from the Confronting COPD survey. Respir Med 2003; 97: S51-59.
6. Wilkinson TM, Donaldson GC, Hurst JR, et al. Early therapy improves outcomes of exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2004; 169: 1298-1303.
7. Global Initiative for Chronic Obstructive Pulmonary Disease (GOLD). April 2001 (. Updated 2004). Global Strategy for the diagnosis, management and prevention of Chronic Obstructive Pulmonary Disease. NHLBI/WHO workshop report. Avaible at: http://www.goldcopd.org/uploads/users/files/GOLDWkshp2004Changes.pdf
8. Woodhead M, Blasi F, Ewig S, Huchon G, Ieven M, Ortqvist A, Schaberg T, Torres A, van der Heijden G, Verheij TJ.; European Respiratory Society; European Society of Clinical Microbiology and Infectious Diseases. Guidelines for the management of adult lower respiratory tract infections. Eur Respir J 2005; 26: 1138-1180.
9. Vollenweider DJ, Jarrett H, Steurer-Stey CA, et al. Antibiotics for exacerbations of chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews 2012,. Issue 12. Art. No.: CD010257. DOI: 10.1002/14651858.CD010257.
10. Nouira S, Marghli S, Belghith M, et al. Once daily oral ofloxacin in chronic obstructive pulmonary disease exacerbation requiring mechanical ventilation: a randomised placebo-controlled trial. Lancet 2001; 358: 2020-2025.
11. Leuppi JD, Schuetz P, Bingisser R, et al. Short-term vs conventional glucocorticoid therapy in acute exacerbations of chronic obstructive pulmonary disease: The REDUCE randomized clinical trial. JAMA 2013; 309: 2223-2231.
12. Niewoehner DE, Erbland ML, Deupree RH, et al. Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease. Department of Veterans Affairs Cooperative Study Group. N Engl J Med 1999; 340: 1941-1947.
13. Schweiger TA, Zdanowicz M. Systemic corticosteroids in the treatment of acute exacerbations of chronic obstructive pulmonary disease. Am J Health Syst Pharm 2010; 67: 1061-1069.
14. Aliá I, de la Cal MA, Esteban A, et al. Efficacy of corticosteroid therapy in patients with an acute exacerbation of chronic obstructive pulmonary disease receiving ventilatory support. Arch Intern Med 2011; 171: 1939-1946.
15. Soler N, Esperatti M, Ewig S, et al. Sputum purulence-guided antibiotic use in hospitalised patients with exacerbations of COPD. Eur Respir J 2012; 40: 1344-1353.
16. Stolz D, Christ-Crain M, Bingisser R, et al. Antibiotic treatment of exacerbations of COPD: a randomized, controlled trial comparing procalcitonin-guidance with standard therapy. Chest 2007; 131: 9-19.
17. Daniels JM, Snijders D, de Graaff CS, et al. Antibiotics in addition to systemic corticosteroids for acute exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2010; 181: 150-157.
18. Hosmer D, Lemeshow S. Applied Logistic Regression. New York: Wiley, 1989.
19. Chow AW, Hall CB, Klein JO, et al. Evaluation of new anti-infective drugs for the treatment of respiratory tract infections. Infectious Diseases Society of America and the Food and Drug Administration. Clin Infect Dis 1992; 15 Suppl 1: S62-88.
20. Dewan NA, Rafique S, Kanwar B, et al. Acute exacerbation of COPD: factors associated with poor treatment outcome. Chest 2000; 117: 662-671.
21. Niewoehner DE, Collins D, Erbland ML. Relation of FEV(1) to clinical outcomes during exacerbations of chronic obstructive pulmonary disease. Department of Veterans Affairs Cooperative Study Group. Am J Respir Crit Care Med 2000; 161: 1201-1205.
22. Hurst JR, Vestbo J, Anzueto A, et al. Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) Investigators. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med 2010; 363: 1128-1138.
23. Smith J, Woodcock A. Cough and its importance in COPD. Int J Chron Obstruct Pulmon Dis 2006; 1: 305-314.
24. Pepys MB, Hirschfield GM. C-reactive protein: a critical update. J Clin Invest 2003; 111: 1805-1812.
25. Perera WR, Hurst JR, Wilkinson TM, et al. Inflammatory changes, recovery and recurrence at COPD exacerbation. Eur Respir J 2007; 29: 527-534.
26. Dahl M, Vestbo J, Lange P, et al. C-reactive protein as a predictor of prognosis in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007; 175: 250-255.
27. Ruiz-González A, Lacasta D, Ibarz M, et al. C-reactive protein and other predictors of poor outcome in patients hospitalized with exacerbations of chronic obstructive pulmonary disease. Respirology 2008; 13: 1028-1033.
28. Hurst JR, Perera WR, Wilkinson TM, et al. Systemic and upper and lower airway inflammation at exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2006; 173: 71-78.
29. Peng C, Tian C, Zhang Y, et al. C-reactive protein levels predict bacterial exacerbation in patients with chronic obstructive pulmonary disease. Am J Med Sci 2013; 345: 190-194.
30. Wilson R, Sethi S, Anzueto A, et al. Antibiotics for treatment and prevention of exacerbations of chronic obstructive pulmonary disease. J Infect 2013; 67: 497-515.
31. Wilson R, Anzueto A, Miravitlles M, et al. Moxifloxacin versus amoxicillin/clavulanic acid in outpatient acute exacerbations of COPD: MAESTRAL results. Eur Respir J 2012; 40: 17-27.
32. Ruiz-González A, Giménez A, Gómez-Arbonés X, et al. Open-label, randomized comparison trial of long-term outcomes of levofloxacin versus standard antibiotic therapy in acute exacerbations of chronic obstructive pulmonary disease. Respirology 2007; 12: 117-121.
33. Grassi C, Casali L, Curti E, et al.; SMART Study Group. Studio Multicentrico con Moxifloxacina nel Trattamento delle Riacutizzazioni de Bronchite Cronica. Efficacy and safety of short course (5-day) moxifloxacin vs 7-day ceftriaxone in the treatment of acute exacerbations of chronic bronchitis (AECB). J Chemother 2002; 14: 597-608.
34. Wilson R, Allegra L, Huchon G, et al.; MOSAIC Study Group. Short-term and long-term outcomes of moxifloxacin compared to standard antibiotic treatment in acute exacerbations of chronic bronchitis. Chest 2004; 125: 953-64.
35. Petitpretz P, Choné C., Trémolières F; Investigator Study Group. Levofloxacin 500 mg once daily versus cefuroxime 250 mg twice daily in patients with acute exacerbations of chronic obstructive bronchitis: clinical efficacy and exacerbation-free interval. Int J Antimicrob Agents 2007; 30: 52-59.
36. Agustí A, Edwards LD, Rennard SI, et al.; Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) Investigators. Persistent systemic inflammation is associated with poor clinical outcomes in COPD: a novel phenotype. PLoS One 2012; 7: e37483.